Publications

1. Ihle JN, Keller J, Lee JC, Farrar WL and Hapel AJ:  Purification and biological properties of interleukin 3.  In Goldstein AL and Chirigos M (Eds):  Lymphokine and Thymic Factors:  Their Potential Utilization in Cancer Therapeutics, Raven Press, New York, Vol. 20, p. 77, 1981.
2. Ihle JN, Rebar L, Keller J, Lee JC and Hapel A:  Interleukin 3:  possible roles in the regulation of lymphocyte differentiation and growth.  Immunol. Rev. 63: 5-32, 1982.
3. Ihle JN, Enjuanes L, Lee JC and Keller J:  The immune response to C-type viruses and its potential role in leukemogenesis.  Curr. Top. Microbiol. Immunol. 101:  31-49, 1982.
4. Ihle JN, Keller J, Greenberger JS, Henderson L, Yetter RA and Morse III HC:  Phenotypic characteristics of cell lines requiring interleukin 3 for growth.  J. Immunol. 129:  1377-1383, 1982.
5. Ihle JN, Keller J, Henderson L, Klein F and Palaszynski EW:  Procedures for the purification of interleukin 3 to homogeneity.  J. Immunol. 129:  2431-2436, 1982.
6. Ihle JN, Keller J, Oroszlan, S. Henderson LE, Copeland TD, Fitch F, Prystowsky MB, Goldwasser E, Schrader JW, Palaszynski E, Dy M and Lebel B:  Biologic properties of homogeneous interleukin 3:  I. Demonstration of WEHI-3 growth factor activity, mast cell growth factor activity, p-cell stimulating factor activity, colony-stimulating factor activity and histamine-producing cell stimulating factor activity.  J. Immunol. 131:  282-287, 1983.
7. Ihle JN, Keller J and Palaszynski EW:  Interleukin 3 regulation of a lineage of lymphocytes expressing 20aSDH.  In: Oppenheim JJ and Cohen S (Eds), Interleukins, Lymphokines, and Cytokines, Academic Press, New York, p. 113, 1983.
8. Prystowsky MB, Ihle JN, Otten G, Keller J, Rich I, Naujokas M, Goldwasser E, and Fitch FW:   Two biologically distinct colony stimulating factors are secreted by a T lymphocyte clone.  In: Golde DW and Marks PA (Eds), UCLA Symposia on Molecular and Cellular Biology, New Series, Alan R. Liss Inc., New York, New York, 9:  369, 1983.
9. Ihle JN, Keller J Palaszynski E, Bowlin T, Mural R Medicus R and Morse III HC:  Biochemical and biological properties of interleukin 3.  In: Goldstein AL (Ed), Thymic Hormones and Lymphokines, Plenum Publishing Corp., New York, New York, p. 77, 1983.
10. Ihle JN and Keller J:  The relative roles of interleukins 1, 2 and 3 in the regulation of T cell differentiation.  Kroc Found. Series 18:  399-421, 1984.
11. Ihle JN, Morse III HC, Keller J and Holmes KL:  Interleukin 3 dependent retrovirus induced lymphomas:  loss of the ability to terminally differentiate in response to differentiation factors.  Curr. Top. Microbiol. Immunol. 113:  86-91, 1984.
12. Ihle JN, Weinstein Y, Keller J, Henderson L and Palaszynski E:  Interleukin 3. Methods Enzymol. 116:  540-552, 1985.
13. Ihle JN and Keller J:  Interleukin 3 regulation of hematopoietic stem cell differentiation. In:  Cronkite ED, et al. (Eds),  Hematopoietic Physiology, Alan R. Liss Inc., New York, New York, p. 85, 1985.
14. Ihle JN, Keller J, Rein A, Cleveland J, and Rapp U:  Interleukin 3 regulation of the growth of normal and transformed hematopoietic cells. Cancer Cells:  Growth Factors and Transformation, Cold Spring Harbor Laboratory Publications, Springer Verlag Inc., New York, New York, p. 211, 1985.
15. Ihle JN, Keller J and Coffman R:  Characteristics of hematopoietic stem cell differentiation-induced in vitro by interleukin 3.  In: Murakami H (Ed), Cells in Defined Environments, Springer Verlag Inc., New York, New York, 1985.
16. Ihle JN and Keller J:  Interleukin 3 regulation of hematopoietic stem cell differentiation.  Prog. Clin. Biol. Res. 184:  85-94, 1985.
17. Keller JR, Weinstein Y, Hursey ML and Ihle JN:  Interleukin 2 and 3 regulate the in vitro proliferation of two distinguishable populations of 20 alpha hydroxysteroid dehydrogenase-positive cells.  J. Immunol. 135:  1864-1871, 1985.
18. Rein A, Keller J, Schultz AM, Holmes KL, Medicus R and Ihle JN:  Infection of imune mast cells by Harvey sarcoma virus:  immortalization without loss of requirement for interleukin-3.  Mol. Cell. Biol. 5:  2257-2264, 1985.
19. Ihle JN, Keller J, Rein A, Pierce J, and Rapp U:  The effects of transforming retroviruses on mast cell growth and IL-3 dependence.  In:  Befus AD, et al. (Eds), Mast Cell Differentiation and Heterogeneity, Raven Press, New York, New York, p. 45, 1986.
20. Brownwell E, Mathieson B, Young HA, Keller J, Ihle JN and Rice NR:  Detection of c-rel-related transcripts in mouse hematopoietic tissues, fractionated lymphocyte populations and cell lines.  Mol. Cell. Biol. 7:  1304-1309, 1987.
21. Keller JR, Mantel C, Sing GK, Ellingsworth LR, Ruscetti SK and Ruscetti FW:  Transforming growth factor ß1 selectively regulates early murine hematopoietic progenitors and inhibits the growth of IL-3-dependent myeloid leukemia cell lines.  J. Exp. Med. 168:  737-750, 1988.
22. Ruscetti F, Sing G, Ellingsworth L, Ruscetti S and Keller J:  Transforming growth factor ß:  a selective growth inhibitor for hematopoietic progenitor cells.  In: Monokines and Other Non-Lymphocytic Cytokines, Alan R. Liss, Inc., New York, NY, pp. 307-312, 1988.
23. Sing GK, Keller JR, Ellingsworth LR and Ruscetti FW:  Transforming growth factor ß selectively inhibits normal and leukemic human bone marrow cell growth in vitro.  Blood 72:  1504-1511, 1988.
24. Ruscetti FW, Sing GK, Ellingsworth LR and Keller JR:  Transforming growth factor ß:  a negative regulator of normal and leukemic hematopoietic progenitor cell growth. In:  Baum SJ, et al. (Eds), Experimental Hematology Today, Springer Verlag, New York, NY, p. 119, 1988.
25. Keller JR, Sing GK, Ellingsworth LR and Ruscetti FW:  Transforming growth factor ß:  possible roles in the regulation of normal and leukemic hematopoietic cell growth.  J. Cell. Biochem. 39:  175-184, 1989. 
26. Ruscetti F, Sing G, Burke P, Bettens F, Schlick E, Ruscetti S and Keller J:  Role of biologic response modifiers in the growth and differentiation of myeloid leukemic cells. Curr. Top. Microbiol. Immunol. 149:  165-172, 1989.
27. Sing GK, Keller JR, Ellingsworth LR and Ruscetti FW:  Transforming growth factor-b1 enhances the suppression of human hematopoiesis by tumor necrosis factor-a or recombinant interferon-a.  J. Cell. Biochem. 39:  107-115, 1989.
28. Goey H, Keller JR, Back T, Longo DL, Ruscetti FW and Wiltrout RH:  Inhibition of early murine hemopoietic progenitor cell proliferation after in vivo locoregional administration of transforming growth factor-B1.  J. Immunol. 143:  877-880, 1989.
29. Talmadge JE, Schneider M, Keller J, Ruscetti F, Longo D, Pennington R, Bowersox O, and Tribble H:  Myelostimulatory activity of recombinant human interleukin-2 in mice. Blood 73:  1458-1467, 1989.
30. Birchenall-Roberts MC, Engelmann GL, Keller JR, Lohrey N and Ruscetti FW:  Retroviral v-myc infection of primary fetal liver cells:  transformation of monocytes in vitro.  Oncogene 4:  731-735, 1990.
31. Keller JR and Ihle JN:  A unique pathway of IL-3 driven hematopoietic differentiation.  J. Immunol. 143:  4025-4033, 1990.
32. Keller JR, Mcniece IK, Sill KT, Ellingsworth LR, Quesenberry PJ, Sing GK and Ruscetti FW:   Transforming growth factor ß directly regulates primitive murine hematopoietic cell proliferation.  Blood 75:  596-602, 1990.
33. Keller JR, Ruscetti SK, and Ruscetti FW:  Introduction of v-abl oncogene induces monocytic differentiation of an IL-3-dependent myeloid progenitor cell line.  Oncogene 5:  549-555, 1990.
34. Dubois CM, Ruscetti FW, Palaszynski EW, Falk LA, Oppenheim JJ and Keller JR:  Transforming growth factor b is a potent inhibitor of interleukin 1 (IL-1) receptor expression:  proposed mechanism of inhibition of IL-1 action.  J. Exp. Med. 172:  737-744, 1990.
35. Smith MR, Muegge K, Keller JR, Kung HF, Young HA and Durum SK:  Direct evidence for an intracellular role for IFN-g.  Microinjection of human IFN-g induces Ia expression on murine macrophages.  J. Immunol. 144:  1777-1782, 1990.
36. Keller JR, Sing GK, Ellingsworth LR, Ruscetti SK and Ruscetti FW:  Two forms of transforming growth factor-b are equally potent selective growth inhibitors of early murine hematopoiesis.  Ann. NY Acad. Sci. 593:  172-180, 1990.
37. Paul CC, Keller JR, Armpriester JM and Baumann MA:  Epstein-Barr virus transformed B lymphocytes produce interleukin-5.  Blood 75:  1400-1403, 1990.
38. Oppenheim JJ, Dubois CM, Ruscetti FW and Keller JR:  Regulation of the production and receptors for interleukin 1, and tumor necrosis factor.  Prog. Clin. Biol. Res. 349:  183-194, 1990.
39. Futami H, Jansen R, MacPhee MJ, Keller J, McCormick K, Longo DL, Oppenheim JJ, Ruscetti FW and Wiltrout RH:   Chemoprotective effects of recombinant human IL-1a in cyclophosphamide-treated normal and tumor-bearing mice.  Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy.  J. Immunol. 145:  4121-4130, 1990.
40. Sing GK, Ruscetti FW, Beckwith M, Keller JR, Ellingsworth L, Urba WJ and Longo DL:  Growth inhibition of a human lymphoma cell line:  induction of a transforming growth factor-b-mediated autocrine negative loop by phorbol myristate acetate.  Cell Growth Differ. 1:  549-557, 1990.
41. Dubois CM, Ruscetti FW, Palaszynski EW, Falk LA, Oppenheim JJ and Keller JR:  Down regulation of interleukin-1 receptor expression by transforming growth factor beta. In:  Molecular and Cellular Biology of Cytokines, Wiley-Liss, pp. 137-142, 1990.
42. Ruscetti FW, Dubois C, Falk LA, Jacobsen SE, Wiltrout R and Keller JR:  In vivo and in vitro effects of TGF b1 on normal and neoplastic hematopoiesis.  Ciba Found. Symp. 157:  212-227, 1991.
43. Oppenheim JJ, Dubois CM, Neta R, Keller JR, Falk LA and Ruscetti FW:  Suppressive effects of transforming growth factor b (TGFb) on the expression of interleukin 1 receptors (IL-1R).  In: Hojo K, Kasakura S (Eds), Proceedings of the Fifth Annual Meetings of Japan Society for Basic Reproductive Immunology and the Japan Society for Medical Reproductive Immunology, pp. 33-38, 1990.
44. Ruscetti FW, Jacobsen SEW, Birchenall-Roberts M, Broxmeyer H, Engelman G, Dubois C and Keller JR:  Role of transforming growth factor b in regulation of hematopoiesis. In: Anagostou A (Ed), Negative Regulators of Hematopoiesis, Ann. NY Acad. Sci. 628:  31, 1991.
45. Jacobsen SEW, Ruscetti FW, Dubois CM, Lee J, Boone TC and Keller JR:  Transforming growth factor-b trans-modulates the expression of colony stimulating factor receptors on murine hematopoietic progenitor cell lines.  Blood 77:  1706, 1991.
46. Birchenall-Roberts MC, Falk LA, Kasper J, Keller J, Faltynek CR and Ruscetti FW:  Differential expression of transforming growth factor-b1 (TGF-b1) receptors in murine myeloid cell lines transformed with oncogenes.  J. Biol. Chem. 266(15):   9617, 1991.
47. Hestdal K, Ruscetti FW, Ihle JN, Jacobsen SEW, Dubois CM, Kopp WC, Longo DL and Keller JR:  Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells.  J. Immunol. 147:  22, 1991.
48. Jacobsen SEW, Keller JR, Ruscetti FW, Kondaiah P, Roberts AB and Falk LA:  Bidirectional effects of TGF-b on colony-stimulating factor induced human myelopoiesis in vitro:  differential effects of distinct TGF-b isoforms.  Blood 78(9):  2239, 1991.
49. Jansen R, Damia G, Keller J, Futami H, Goey H, Back TT, Longo DL, Ruscetti FW and Wiltrout R:  Effects of recombinant transforming growth factor b1 (rTGFb1) on hematologic recovery following treatment of mice with 5-fluorouracil.  J. Immunol. 147:  3342, 1991.
50. Dubois CM, Ruscetti FW, Keller JR, Oppenheim JJ, Hestdal K, Chizzonite R and Neta R:  In Vivo IL-1 Administration indirectly promotes type II IL-1R expression on hematopoietic progenitor cells:  novel mechanisms for the hematopoietic effects of IL-1.  Blood 78: 2841, 1991.
51. Jacobsen SEW, Ruscetti FW, Longo DL and Keller JR:  The antineoplastic dolastatins are potent inhibitors of hematopoietic progenitor cells.  J. Natl. Cancer Inst. 83:  1672, 1991.
52. Keller JR, Jacobsen SEW, Sill KT, Ellingsworth LR and Ruscetti FW:  Stimulation of granulopoiesis by transforming growth factor b:  synergism with granulocyte-macrophage colony stimulating factor.  Proc. Natl. Acad. Sci. 88:  7190, 1991.
53. Keller JR, Jacobsen SEW, Dubois CM, Hestdal K and Ruscetti FW:  Transforming growth factor-b:  a bidirectional regulator of hematopoietic cell growth.  Intl. J. Cell Cloning 10:  2, 1991.
54. Jacobsen SEW, Ruscetti FW, Dubois CM and Keller JR:  Tumor necrosis factor alpha is a bidirectional modulator of CSF receptor expression on hematopoietic progenitor cells:  proposed mechanisms of action for its multifunctional effects in hematopoiesis.  J. Exp. Med. 175: 1759, 1991.
55. Ewel CH, Kuhns DB and Keller JR:  Clinical monitoring of immune and hematopoietic function. In:  Rose NR, Friedman H, and Fahey JL (Eds), Manual of Clinical Laboratory Immunology, American Society of Microbiology, pp. 923-932, 1991.
56. Damia G, Komschilies KL, Futami H, Back T, Gruys ME, Longo DL, Keller JR, Ruscetti FW and Wiltrout R:  Prevention of acute chemotherapy-induced death in mice by recombinant human interleukin 1:  protection from hematological and nonhematological Toxicities.  Cancer Res. 52:  4082, 1992.
57. Dubois CM, Ruscetti FW, Jacobsen SEW, Oppenheim JJ and Keller JR:  Hematopoietic growth factors upregulate the p65 type II interleukin-1 receptor on bone marrow progenitor cells in vitro.  Blood 80:  600, 1992.
58. Kmiecik TE, Keller JR, Rosen E and Vande Woude GF:  Hepatocyte growth factor is a synergistic factor for the growth of hematopoietic progenitor cells.  Blood 80: 2454, 1992.
59. Jacobsen SEW, Ruscetti FW, Dubois CM, Wine J and Keller JR:  Induction of colony stimulating factor receptor expression on hematopoietic progenitors cells:  proposed mechanism for growth factor synergism.  Blood 80: 678, 1992.
60. Murphy WJ, Bennett M, Kumar V, Keller J, Harrison CL and Longo DL:  Activated natural killer cells can support hematopoiesis in vitro and promote allogeneic bone marrow engraftment in vivo.  Blood 80: 670, 1992.
61. Hestdal K, Jacobsen SEW, Ruscetti FW, Dubois CM, Longo DL, Chizzonite R, Oppenheim JJ and Keller JR:  In vivo effect of interleukin-1a on hematopoiesis:  role of colony-stimulating factor receptor modulation.  Blood 80: 2486, 1992.
62. Ott DE, Keller J, Sill K and Rein A:  Phenotypes of murine leukemia virus-induced tumors:  influence of 3' viral coding sequences.  J. Virol. 66:  6107, 1992.
63. Ruscetti FW, Dubois CM, Jacobsen SEW and Keller JR:  Transforming growth factor b and interleukin 1:  a paradigm for opposing regulation of hematopoiesis. In:  Lord B and Dexter TM (Eds),  Growth Factors in Hematopoiesis, Bailliere's Clinical Hematology, W.B. Saunders Company, London, 5:  703, 1991.
64. McNiece IK, Bertoncello I, Keller JR, Ruscetti FW, Hartley CA and Zsebo KM:  Transforming growth factor-b inhibits the action of stem cell factor on mouse and human gematopoietic progenitors.  Intl. J. Cell Cloning 10:  80, 1992.
65. Dubois CM, Neta R, Keller JR, Jacobsen SEW, Oppenheim JJ and Ruscetti FW:  Hematopoietic growth factors and glucocorticoids synergize to mimic the effects of IL-1 on granulocyte differentiation and IL-1 receptor induction on bone marrow cells.  In Vivo Exp. Hematol. 21:  303, 1993.
66. Hestdal K, Jacobsen SE, Ruscetti FW, Longo DL, Boone TC and Keller JR:  Increased granulopoiesis after sequential administration of transforming growth factor-b-1 and granulocyte-macrophage colony-stimulating factor.  Exp. Hematol. 21:  799-805, 1993.
67. Jacobsen SE, Ruscetti FW, Roberts AB and Keller JR:   TGF-beta is a bidirectional modulator of cytokine receptor expression on murine bone marrow cells: differential effects of TGF-beta 1 and TGF-beta 3.  J. Immunol. 151:  4534-4544, 1993.
68. Hestdal K, Welte K, Lie SO, Keller JR, Ruscetti FW and Abrahamsen TG:  Severe congenital neutropenia:  abnormal growth and differentiation of myeloid progenitors to granulocyte colony-stimulating factor (G-CSF) but normal response to G-CSF plus stem cell factor.  Blood 82:  2991-2997, 1993.
69. Grzegorzewski K, Komschilies KL, Mori M, Kaneda K, Usui N, Faltynek CR, Keller JR, Ruscetti FW and Wiltrout R:  Administration of recombinant human interleukin-7 to mice induces the exportation of myeloid progenitor cells from the bone marrow to peripheral sites.  Blood 83:  377-385, 1994.
70. Ruscetti FW, Jacobsen SEW, Dubois CM, Hestdal K and Keller JR:  Hematopoietic cell growth is regulated by a balance of positive and negative regulators:  potential role for receptor modulation.  In:  Najman, A., Guidon, M. and Lemoine, F. (Eds.).  The Negative Regulation of Hematopoietic Cell Growth and Differentiation.  John Livey Eurotext LTD, Montrouge, France.  p. 23-30, 1993.
71. Hestdal K, Ruscetti FW, Chissonite R, Ortiz M, Gooya JM, Longo DL and Keller JR:  Interleukin-1 (IL-1) directly and indirectly promotes hematopoietic cell growth through type 1 IL-1 receptor.  Blood 84:  125-132, 1994.
72. Dubois CM, Ruscetti FW, Stankova J and Keller JR:  Transforming growth factor- beta regulates c-kit message stability and cell-surface protein expression in hematopoietic progenitors.  Blood 83:  3138-3145, 1994.
73. Jacobsen SE, Ruscetti FW, Ortiz M, Gooya JM and Keller JR:  The growth response of Lin- Thy-1+ hematopoietic progenitors to cytokines is determined by the balance between synergy of multiple stimulators and negative cooperation of multiple inhibitors.  Exp. Hematol. 22:  985-989, 1994.
74. Keller JR, Bartelmez SH, Sitnicka E, Ruscetti FW, Ortiz M, Gooya JM and Jacobsen SE:  Distinct and overlapping effects of macrophage inflammatory protein-1 alpha and transforming growth factor-beta on hematopoietic progenitor/stem cell growth.  Blood 84:  2175-2181, 1994.
75. Grzegorzewski K, Ruscetti FW, Usui N, Damia G, Longo DL, Carlino JA, Keller JR and Wiltrout R:  Recombinant transforming growth factor b1 and b2 protect mice from acutely lethal doses of 5-fluorouracil and doxorubicin.  J. Exp. Med. 180:  1047-1057, 1994.
76. Tiberghien P, Reynolds CW, Keller J, Spence S, Deschaseaux M, Certoux JM, Contassot E, Murphy WJ, Lyons R, Chiang Y, Herve P, Longo DL and Ruscetti FW:  Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes:  an approach for specific in vivo donor T-cell depletion after bone marrow transplantation?  Blood 84:  1333-1341, 1994.
77. Ott DE, Keller J and Rein A:  10A1 MuLV induces a murine leukemia that expresses hematopoietic stem cell markers by a mechanism that includes fli-1 integration.  J. Virol. 205:  563-568, 1994.
78. Jacobsen SE, Ruscetti FW, Okkenhaug C, Lien E, Ortiz M, Veiby OP and Keller JR:  Distinct and direct synergistic effects of IL-1 and IL-6 on proliferation and differentiation of primitive murine hematopoietic progenitor cells in vitro.  Exp. Hematol. 22:  1064-1069, 1994.
79. Grzegorzewski KJ Komschilies KL, Jacobsen SE, Ruscetti FW, Keller JR and Wiltrout R:  Mobilization of long-term reconstituting hematopoietic stem cells in mice by recombinant human interleukin 7.  J. Exp. Med. 181:  369-374, 1995.
80. Jacobsen FW, Keller JR, Ruscetti FW and Jacobsen SE:  Direct synergistic effects of IL-4 and IL-11 on proliferation of primitive hematopoietic progenitor cells.  Exp. Hematol. 23:  990-995, 1995.
81. Muszynski KW, Ruscetti FW, Heidecker G, Rapp U, Troppmair J, Gooya JM and Keller JR:  Raf-1 protein is required for growth factor-induced proliferation of hematopoietic cells.  J. Exp. Med. 181:  2189-2199, 1995.
82. Keller JR, Ortiz M and Ruscetti FW:  Steel factor (c-kit ligand) promotes the survival of hematopoietic progenitor/stem cells in the absence of cell division.  Blood 86:  1757-1764, 1995.
83. Linnekin D, Keller JR, Ferris DK, Mou SM, Broudy V and Longo DL:  Stem cell factor induces the phosphorylation of a 200 kDa protein which associates with C-kit.  Growth Factors 12:  57-67, 1995.
84. Spence SE, Keller JR, Ruscetti FW, Czarra KT, Gooya JM, Funakoshi S, Longo DL and Murphy WJ:  Engraftment of SCID mice by human bone marrow hematopoietic cells cultured in vitro:  an in vivo model for human gene transfer.  Leukemia 9S1:  43-47, 1995.
85. Swarzenberger P, Spence SE, Gooya JM, Michiel D, Curiel DT, Ruscetti FW and Keller JR:  Targeted gene transfer to human hematopoietic progenitor cell lines through the c-kit receptor.  Blood 87:  472-478, 1996.
86. Keller JR, Ruscetti FW, Heidecker G, Linnekin DM, Rapp U, Troppmair, J., Gooya, J. and Muszynski KW:  The effect of c-raf antisense oligonucleotides on growth factor-induced proliferation of hematopoietic cells.  Curr. Top. Microbiol. Immunol. 211:  43-53, 1996.
87. Keller JR, Bartelmez SH, Sitnicka E, Ruscetti FW, Ortiz M, Gooya JM, Jacobsen SE:  Distinct and overlapping direct effects of macrophage inflammatory protein-1a and transforming growth factor b on hematopoietic progenitor/stem cell growth. In:  Spivak JD (Ed), The Yearbook of Hematology,  Mosby-Year Book Inc., Chicago, IL, p. 92, 1996.
88. Weiler SR, Mou S, DeBerry CS, Keller JR, Ruscetti FW, Ferris DK, Longo DL and Linnekin D:  JAK2 is associated with the c-kit proto-oncogene product and is phosphorylated in response to stem cell factor.  Blood 87:  3688-3693, 1996.
89. Neta R, Keller JR, Ali N, Blanchette F and Dubois CM:  Contrasting mechansims of myeloprotective effects of IL-1 against ionizing radiation and cytoablative 5-fluorouracil. Radiat. Res. 145:  624-631, 1996.
90. Schwarzenberger P, Spence S, Lohrey N, Kmiecik T, Longo DL, Murphy WJ, Ruscetti FW and Keller JR:  Gene transfer of multidrug resistance into a factor-dependent human hematopoietic progenitor cell line:  in vivo model for genetically transferred chemoprotection.  Blood 87:  2723-2731, 1996.
91. Keller JR, Gooya JM, Ruscetti FW:  Direct synergistic effects of leukemia inhibitory factor on hematopoietic progenitor cell growth:  Comparison with other hematopoietins that use the gp130 receptor subunit. Blood 88:  863-869, 1996.
92. Linnekin D, Weiler SR, Mou S, DeBerry CS, Keller JR, Ruscetti FW, Ferris DK and Longo DL:  JAK2 is constitutively associated with c-kit and is phosphorylated in response to stem cell factor.  Acta Hematol. 95:  224-228, 1996.
93. Grzegorzewski KJ, Komschlies KL, Franco JL, Ruscetti FW, Keller JR and Wiltrout R:  Quantitative and cell-cycle differences in progenitor cells mobilized by recombinant human interleukin-7 and recombinant human granulocyte colony- stimulating factor. Blood 88:  4139-4148, 1996.
94. Drize NJ, Keller JR, Chertkov JL:  Local and clonal analysis of hematopoietic system shows that multiple small short-living clones maintain life-long hematopoieisis in reconsitituted mice.  Blood 88:  2927-2938, 1996.
95. Muszynski KW, Ruscetti FW, Gooya JM, Linnekin DM and Keller JR:  Raf-1 protein is required for growth factor-induced proliferation of primitive hematopoietic progenitors stimulated with synergistic combinations of cytokines.  Stem Cells 15:  63-72, 1997.
96. Linnekin D, Mou S, DeBerry CS, Weiler S, Ferris D, Ruscetti F, Keller JR and Longo DL:  JAK2 is constitutively associated with c-Kit and is phosphorylated in response to stem cell factor.  In:  Abraham et al. (Eds), The Molecular Biology of Hematopoiesis, Plenum Press, NY, pp. 369-376, 1996.
97. Keller JR, Ruscetti FW, Grzegorzewski K, Wiltrout R, Bartelmez SH, Sitnicka E and Jacobsen SE:  Transforming growth factor-b, tumor necrosis factor-a and macrophage inflammatory protein-1a are bidirectional regulators of hematopoietic cell growth.  In:  Garland JM, et al. (Eds), Colony Stimulating Factors Molecular and Cellular Biology, Marcel Dekker, Inc., New York, NY, pp. 445-467, 1997.
98. Linnekin D, Mou S, Deberry CS, Weiler SR, Keller JR, Ruscetti FW and Longo DL:  Stem cell factor, the JAK-STAT pathway and signal transduction.  Leuk. Lymphoma 27:  439-444, 1997.
99. Spence SE, Keller JR, Ruscetti FW, McCauslin CS, Gooya JM, Funakoshi S, Longo DL, and Murphy WJ:  Engraftment of ex vivo expanded and cycling human cord blood hematopoietic progenitor cells in SCID mice.  Exp. Hematol. 26:  507-514, 1998.
100. Williams SC, Du Y, Schwartz RC, Weiler SR, Keller JR and Johnson PF:  C/EBPe is a myeloid-specific activator of cytokine, chemokine, and macrophage-colony-stimulating factor receptor genes.  J. Biol. Chem. 273:  13493-13501, 1998.
101. Resnick JL, Ortiz M, Keller JR and Donovan PJ:  Role of fibroblast growth factors and their receptors in primordial germ cell growth.  Biol. Reprod. 59:  1224-1229, 1998.
102. Weiler SR, Gooya JM, Ortiz M, Tsai S, Collins SJ and Keller JR:  D3:  a gene induced during myeloid cell differentiation of Linlo c-Kit+ Sca-1+ progenitor cells.  Blood 93:  527-536, 1999.
103. Ortiz M, Wine JW, Lohrey N, Ruscetti FW, Spence SE and Keller JR:  Functional characterization of a novel hematopoietic stem cell and its place in the c-Kit maturation pathway in bone marrow cell development.  Immunity 10:  173-182, 1999.
104. Smith JS, Keller JR, Lohrey NC, McCauslin CS, Ortiz M, Cowan, K and Spence SE:  Redirected infection of directly biotinylated recombinant adenovirus vectors through cell surface receptors and antigens.  Proc. Nat. Acad. Sci. USA 96:  8855-8860, 1999.
105. Du Y, Tsai S, Keller JR and Williams SC:  Identification of an interleukin-3-regulated aldoketo reductase gene in myeloid cells which may function in autocrine regulation of myelopoiesis.  J. Biol. Chem. 275:  6724-6732, 2000.
106. Welniak LA, Tian ZG, Sun R, Keller JR, Richards S, Ruscetti FW and Murphy WJ:  Effects of growth hormone and prolactin on hematopoiesis.  Leuk. Lymphoma 38:  435-445, 2000.
107. Keller JR and Linnekin DM:  Stem Cell Factor.  In:  Oppenheim JJ, et al. (Eds), The Cytokine Reference:  A Compendium of Cytokines and Other Mediators of Host Defense, Academic Press, London, UK, pp. 896-897, 2001.
108. Linnekin DM and Keller JR:  Stem cell factor receptor. In:  Oppenheim JJ, et al. (Eds).  The Cytokine Reference:  A Compendium of Cytokines and Other Mediators of Host Defense, Academic Press, London, UK, pp. 1913-1934, 2001.
109. Keller JR:  Stem cell quiescence and activation.  Molec. Aspects of Immuno.  1(5):  217-220, 2001.
110. Spence SE, Lohrey NC, Ortiz M, Gooya J and Keller JR:  Detection of growth factor receptor RNA in individual hematopoietic cells by in situ RT-PCR; comparison with RT-PCR.  J. Immunol. Methods 257:  123-136, 2001.
111. Du Y, Campbell JL, Nalbant D, Youn H, Bass AC, Cobos E, Tsai S, Keller JR and Williams SC:  Mapping gene expression patterns during myeloid differentiation using the EML hematopoietic progenitor cell line.  Exp. Hematol. 30:  649-658, 2002.
112. Liu P, Keller JR, Ortiz M, Tessarollo L, Rachel RA, Nakamura T, Jenkins NA and Copeland NG:  Bcl11a is essential for normal lymphoid development.  Nat. Immunol. 4:  525-532, 2003.
113. McCauslin CS, Wine J, Cheng L, Klarmann KD, Candotti F, Clausen PA, Spence SE and Keller JR:  In vivo retroviral gene transfer by direct intrafemoral injection results in correction of the SCID phenotype in Jak3 knockout animals.  Blood 102:  843-848, 2003.
114. Klarmann K, Ortiz M, Davis M and Keller JR:  Identification of in vitro growth conditions for c-Kit-negative hematopoietic stem cells.  Blood 102:  3120-3128, 2003.
115. Asefa B, Klarmann KD, Copeland NG, Gilbert DJ, Jenkins NA and Keller JR:  The interferon-inducible p200 family of proteins:  A perspective on their roles in cell cycle regulation and differentiation.  Blood Cells Mol. Dis. 32:  155-167, 2004.
116. Sharov A, Piao1 Y, Matoba R, Dudekula DB, Qian Y, VanBuren V, Falco G, Martin PR, Stagg CA, Bassey UC, Wang Y, Carter MG, Hamatani T, Aiba K, Akutsu H, Sharova L, Tanaka TS, Kimber WL, Yoshikawa T, Jaradat SA, Pantano S, Nagaraja R, Boheler KR, Taub D, Hodes RJ, Longo DL, Schlessinger D, Keller J, Klotz E, Kelsoe G, Umezawa A, Vescovi AL, Rossant A, Kunath T, Hogan BM, Curci A, D’Urso M, Kelso J, Hide W, and Ko MS:  Transcriptome analysis of mouse stem cells and early embryos.  PloS Bio. 1:  410-419, 2004.
117. Radosevic N, Winterstein D, Keller JR, Neubauer H, Pfeffer K and Linnekin D: JAK2 contributes to the intrinsic capacity of primary hematopoietic cells to respond to stem cell factor.  Exp. Hematol. 32:  149-156, 2004.
118. Jiang Q, Li WQ, Hofmeister RR, Young HA Hodge DR Keller JR, Khaled AR and Durum SK:  Distinct regions of the interleukin-7 receptor regulate different Bcl-2 family members.  Mol. Cell. Biol. 24:  6501-6513, 2004.
119. Li WQ, Jiang Q, Khaled AR, Keller JR, and Durum SK:  Interleukin-7 inactivates the pro-apoptotic protein Bad promoting T cell survival.  J. Biol. Chem. 279:  299160-19166, 2004.
120. Dermott JM, Gooya JM, Asefa B, Weiler SR, Smith M and Keller JR:  Inhibition of growth by p205:  A nuclear protein and putative tumor suppressor expressed during myeloid cell differentiation.  Stem Cells 22:  832-848, 2004.
121. Heath V, Suh HC, Holman M, Renn K, Gooya JM, Parkin S, Klarmann KD, Ortiz M, Johnson P, and Keller J:  C/EBPαdeficiency results in hyperproliferation of hematopoietic progenitor cells and disrupts macrophage development in vitro and in vivo. Blood 104:  1639-1647, 2004.
122. Jiang Q, Li WQ, Aiello FB, Klarmann KD, Keller JR and Durum SK:  Retroviral transduction of IL-7Rα into IL-7Rα-/- bone marrow progenitors:  correction of lymphoid deficiency and induction of neutrophilia.  Gene Ther. 12:  1761-1768, 2005.
123. Leeanansaksiri W, Wang H, Gooya JM, Renn K, Abshari M, Tsai S and Keller JR:  IL-3 induced inhibitor of DNA-binding protein-1 in hematopoietic progenitor cells and promotes myeloid cell development.  J. Immunol. 174:  7014-7021, 2005.
124. Drutskaya MS, Ortiz M, Liepinsh DJ, Kuprash DV, Nedospasov SA and Keller JR:  Inhibitory effects of tumor necrosis factor on hematopoiesis seen in vitro and translated to increased numbers of both committed and multipotent progenitors in TNF-deficient mice.  Exp. Hematol. 33:  1348-1356, 2005.
125. Liepinsh DJ, Grivennikov SI, Klarmann KD, Lagarkova MA, Drutskaya MS, Lockett SJ, Tessarollo L, McAuliffe M, Keller JR, Kuprash DV and Nedospasov SA:  Novel lymphotoxin alpha (Ltά) knockout mice with unperturbed tumor necrosis factor expression:  reassessing the Ltά biological functions.  Mol. Cell. Biol. 26:  4214-4225, 2006.
126. Asefa B, Dermott JM, Kaldis P, Stefanisko K, Garfinkel DJ and Keller JR:  p205 a potential tumor suppressor, inhibits cell proliferation via multiple pathways of cell cycle regulation.  FEBS Lett. 580:  1205-1214, 2006.
127. Suh HC, Gooya J, Renn K, Friedman AD, Johnson PF and Keller JR:  C/EBPα determines hematopoietic cell fate in multipotential progenitor cells by inhibiting erythroid differentiation and inducing myeloid differentiation.  Blood 107:  4308 – 4316, 2006.
128. Berthet C, Klarmann KD, Hilton MB, Suh HC, Keller JR, Kiyokawa H, Kaldis P:  Combined Loss of Cdk2 and Cdk4 Results in Embryonic Lethality and Rb Hypophosphorylation.  Dev. Cell 10:  563-573, 2006.
129. Aiello FB, Keller JR, Klarmann KD, Dranoff G, Mazzucchelli R, Durum SK:  IL-7 Induces Myelopoiesis and Erythropoiesis.  J. Immunology 78:  1553-1563, 2007.
130. Jiang Q, Huang J, Li W, Cavinato T, Keller JR, and Durum SK:  Role of the intracellular domain of IL-7 receptor in T cell development.  J. Immunology 178:  228-232, 2007.
131. Gudmundsson KO, Thorsteinsson L, Sigurjonsson OE, Keller JR, Olafsson K, Egeland T, Gudmundsson S and Rafnar T:  Dlg7, the homologue of the Drosophilia Dlg1 tumor suppressor gene, has a role in stem cell survival and in maintaining stem cell properties. Stem Cells 25:  1498-1506, 2007.
132. Berthet C, Rodriguez-Galan MC, Hodge DL, Gooya J, Pascal V, Young HA, Keller JR, Bosselut R, and Kaldis P:  Hematopoiesis and thymic apoptosis are not affected by the loss of Cdk2.  Molec. Cell. Bio. 27(14):  5079-5089, 2007.
133. Ludlow LE, Purton LE, Klarmann K, Gough HLL, Trapani JA, Keller JR, Clarke CJP, Johnstone RW:  The role of p202 in regulating hematopoietic cell proliferation and differentiation.  J. Interferon & Cytokine Res. 28: 5-11, 2008.
134. Fan T, Schmidtmann A, Zhu H, Suh HC, Gooya J, Keller JR, Xi S, Hong X, Roayaei J, Anver M, Ruscetti S, and Muegge K:  DNA hypomethylation caused by Lsh deletion promotes erythroleukemia development.  Epigenetics 3(3): 134-42, 2008.
135. Ji M, Li H, Suh HC, Klarmann KD, Yokota Y, and Keller JR:  Id2 regulates lymphoid and erythroid development via interaction with different target proteins. Blood 112(4): 1068-77, 2008.
136. Cohen TV, Klarmann KD, Sakchaisri K, Kuhns D, Anver M, Johnson PF, Williams S, Johnson P, Keller JR, Stewart CL:  The Lamin B receptor under the transcriptional control of C/EBP-epsilon is required for morphological but not functional maturation of neutrophils.  Hum. Mol. Genet. 17(19): 2921-33, 2008.
137. Suh HC, Leeanansaksiri W, Ji M, Klarmann KD, Renn K, Gooya J, Smith BD, McNiece I, Lugthart S, Valk P, Delwel R, and Keller JR:  Id1 Immortalizes hematopoietic progenitors in vitro and promotes a myeloproliferative disease in vivo. Oncogene 27: 5612-23, 2008.
138. Suh HC, Ji M, Gooya J, Lee M, Klarmann KD, Keller JR:  Cell-nonautonomous function of Id1 in the hematopoietic progenitor cell niche.  Blood 114(6): 1186-1195, 2009.
139. Li H, Ji M, Klarmann KD, Keller JR:  Repression of Id2 expression by Gfi-1 is required for B-cell and myeloid development.  Blood 116(7): 1060-1069, 2010.
140. Klarmann K, Ji M, Li H, Satyanarayana A, Kim W, Bowers E, Gudmundsdottir B, Keller JR:  Novel Targets in Myelogenous Leukemia: The Id Family of Proteins.    In Tech – Myeloid Leukemia – Basic Mechanisms of Leukemogenesis, Chapter 12: 215-238, 2011.
141. Satyanarayana A, Klarmann K, Gavrilova O, Keller JR:  Ablation of the transcriptional regulator Id1 enhances energy expenditure, increases insulin sensitivity and protects against age and diet induced insulin resistance and hepatosteatosis.  FASEB J.  26(1): 309-323, 2011.
142. Satyanarayana A, Gudmundsson KO, Chen X, Coppola V, Tessarollo L, Keller JR, Hou SX: RapGEF2 is essential for embryonic hematopoiesis but dispensable for adult hematopoiesis.  Blood 116(16): 2921-2931, 2011.
143. Gudmundsson KO, Stull SW, Keller JR:  Transplantation of mouse fetal liver cells for analyzing the function of hematopoietic stem and progenitor cells.  Methods Mol. Biol.  879: 123-133, 2012.
144. Oakley K, Han Y, Vishwakarma B, Bhatia R, Gudmundsson K, Keller JR, Vasko V, Jenkins NA, Copeland NG, and Yang Du: Setbp1 promotes the self-renewal of myeloid progenitors via activation of Hoxa9 and Hoxa10.   Blood 119(25):  6099-6108, 2012.
145. Baba M, Keller JR, Sun HW, Resch W, Kuchen S, Suh HC, Hasumi H, Hasumi Y, Kieffer-Kwon KR, Gonzalez CG, Hughes RM, Klein ME, Oh HF, Bible P, Southon E, Tessarollo L, Schmidt LS, Linehan WM, and Casellas R:  The folliculin-FNIP1 pathway deleted in human Birt-Hogg-Dubé syndrome is required for murine B-cell development.  Blood 120(6): 1254-61, 2012.
146. Balamurugan K, Sharan S, Klarmann KD, Zhang Y, Coppola V, Summers GH, Roger T, Morrison DK, Keller JR, Sterneck E:  FBXW7α attenuates inflammatory signaling by downregulating C/EBPδ and its target gene Tlr4.  Nat. Commun. 4: 1662, 2013.
147. Sirt1 ablation promotes stress-induced loss of genetic and epigenetic hematopoietic stem cell maintenance. Singh, S.K., Williams, C.A., Klarmann, K.D., Keller, J.R., and Philipp Oberdoerffer.  Journal Exp. Med. 210(5):987-1001, 2013.
148. Sun L, Mathews LA, Cabarcas SM, Zhang X, Yang A, Zhang Y, Young MR, Klarmann KD, Keller JR, Farrar WL:  Epigenetic Regulation of SOX9 by the NF-κB Signaling Pathway in Pancreatic Cancer Stem Cells. Stem Cells, Aug; 31(8), p1454-66, 2013. 
149. Huggins CJ, Malik R, Lee S, Salotti J, Thomas S, Martin N, Quiñones OA, Alvord WG, Olanich ME, Keller JR, Johnson PF. C/EBPγ Suppresses Senescence and Inflammatory Gene Expression by Heterodimerizing with C/EBPβ. Mol. Cell. Biol., Aug; 33 (16), p3242-58, 2013 Jun 17. [Epub ahead of print]
150. Kim, W-I, Klarmann, K.D., Keller, J.R.Gfi-1 regulates the erythroid transcription factor network through Id2 repression in hematopoietic progenitor cells. (Blood, In Revision)
151. Gudmundsson, K.O., Gudmundsdottir, B., Klarmann, K.D., Du, Y., Coppola, V., Tessarollo, L., Thorsteinsson, L., Sigurjonsson, O.E., Gudmundsson, S., Rafnar, T., Keller, J.R.The Zinc Finger Protein Pogz is Essential for Normal Erythroid Development and Regulates Fetal Hemoglobin Expression. (Submitted)
152. Fan-ching, L., Bahara, S.,Hodge, D.L., Boelte, K., Keller, J.R., Young, H.A.IFN-gamma causes aplastic anemia by altering HSC composition and interrupting lineage differentiation. (Submitted)
153. Bosley. A.D., Das, S., Alvord, G.W., Quiñones, O., Ye.X., Xiao, Z., Gudmundsdottir, B., Gudmundsson, K.O., Keller, J.R., Esposito, D., Veenstra, T.D., and Andresson, T. A statistical approach to mitigate background proteome variability in the identification of interacting partners for the model protein PogZ (? Where is it).